Innovation, competition and regulatory change: Assessing interrelationships at the industry level

Abstract

and Key Results■ This paper focuses on the overall themes of the issue to examine the interrelationships between innovation, competition and regulatory change in international business.■ It provides a synthesis by highlighting recent interlinked developments in two contrasting industries dominated by large multinationals -pharmaceuticals and automotives, with specific reference to cars.■ This industry based assessment highlights the technical, economic and regulatory forces that have together changed the business environment, innovation processes and nature of competition in the pharmaceutical and automotive industries.

University Faculty and the Value of Their Intellectual Property: Comparing IP in Teaching and Research

“…IP rules, for both protection and access, are both a cause and a result of economic activity: it is hard to tell when changes in markets for goods and services affect IP policies and practices and when changes in IP policies and practices affect markets for goods and services. Growth in economic development and IP protections have been uneven, varying not just by region (developed versus developing parts of the world), but also by industrial sector, and are found especially among knowledge intensive industries such as genomics and digital technology, and in places hospitable to them, such as Singapore (Baber, ; Fai & Morgan, ), and Silicon Valley. Arguments for IP access , on the other hand, are more in evidence in regions and communities where basic knowledge via schooling is most in demand and least in evidence.…”

Impact of Economic, Social and Environmental Variables on Competitiveness of Automotive Industry: Evidence from Panel Data

“…The application of emission standard technologies seemed to have minor effect on the average sale of cars. Fai and Morgan (2007) examined the relationships among competition, innovation and change in regulation in business environment at international level. These factors have strong impact on automobile industry and can lead to give a direction for the future polices regarding this sector.…”

Money for nothing? Risks in biopharmaceutical companies from the perspective of public financiers

“…12,13 The discovery and development phases mainly involve technical risks regarding the safety and effi cacy of the potential product, for example, whereas in the commercialisation phase they are related more to competition, fi nancial return and marketing. 5,6 Regulatory risk, related to patent legislation, for example, is present at each stage of the process.…”

“…5,6 Regulatory risk, related to patent legislation, for example, is present at each stage of the process. 13 The aim during the discovery stage is to identify new promising chemical and biological properties of either previously known or newly synthesised substances.…”